NVCR News and Press, NovoCure Limited From 01/20/22

Shares of Novocure Limited (NASDAQ: NVCR) are jumping 12.9% higher as of 11:09 a.m. ET on Thursday. The solid gain came after investment firm Truist Financial upgraded the stock from a hold to a buy recommendation. Truist kept its 12-month price target for the stock at $125, which r...

Preliminary full year 2021 net revenues of $535 million and fourth quarter net revenues of $133 million DMC interim analysis for INNOVATE-3 pivotal trial in ovarian cancer anticipated in early Q2 2022 given limited total number of events to date in fast-recruiting trial ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pharmaceutical stocks have been center stage since the start of Covid-19. Biopharma companies have been striving to develop and commercialize life-saving vaccines and antiviral pills to fight the pandemic. In the past sev...

Novocure (NASDAQ: NVCR) announced today it will participate in the 40 th Annual J.P. Morgan Virtual Healthcare Conference on January 10 through January 13, 2022. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analy...

Novocure (NASDAQ:NVCR) signed a purchase and sale agreement to acquire and construct an office building at 64 Vaughan Mall, in the heart of downtown Portsmouth, New Hampshire. The purchase price of the property is $9.5M. On agreement closure, Novocure will enter into a construction ...

The property will provide space for Novocure’s growing workforce, and house a world-class training and development center Novocure (NASDAQ: NVCR) today announced that the company has signed a purchase and sale agreement to acquire and construct an office building at 6...

Novocure (NASDAQ: NVCR) today announced the 4 th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The program represents a joint effort with the American Association for Cancer Research (AACR) to promote and support innovative research on Tumor Treating Fields...

They may be the companies behind some of the U.S.'s most compelling growth stock stories. But shares of NovoCure (NASDAQ: NVCR) , Pinterest (NYSE: PINS) , and MarketAxess (NASDAQ: MKTX) have been strangely poor performers this year, with prices down 46%, 39%, and 38%...

NovoCure (NASDAQ: NVCR) was one of the better-performing stocks of early 2021, but the big gains came to an end in June. Since peaking this summer, shares have lost more than 58% of their value. Is the recent plunge an opportunity to buy a great medical device stock on sale, or ...

Evercore ISI says that getting some feedback on particulars around one oncology company's fiscal 2020 led it to take a deeper dive into revenue drivers - and to slash revenue estimates for the coming years. That's NovoCure (NASDAQ:NVCR), and after noting that the company's fiscal year saw a b...